Is R1 vascular hepatectomy for hepatocellular carcinoma oncologically adequate? Analysis of 327 consecutive patients.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
05 2019
Historique:
received: 07 09 2018
revised: 23 11 2018
accepted: 04 12 2018
pubmed: 30 1 2019
medline: 1 1 2020
entrez: 30 1 2019
Statut: ppublish

Résumé

R1 vascular resection for liver tumors was introduced in the early twenty-first century. However, its oncologic adequacy remains controversial. The aim of this study was to determine the oncologic adequacy of R1 vascular hepatectomy in hepatocellular carcinoma patients. A prospective cohort of patients with hepatocellular carcinoma resected between the years 2005 and 2015 was reviewed. R0 was any resection with a minimum 1 mm of negative margin. R1 vascular was any resection with tumor exposure attributable to the detachment from major intrahepatic vessel. R1 parenchymal was any resection with tumor exposure at parenchymal margin. The end points were the calculation of the local recurrence of R0, R1 parenchymal, and R1 vascular hepatectomy and their prognostic significances. We analyzed 327 consecutive patients with 532 hepatocellular carcinoma and 448 resection areas. We found that 205 (63%) resulted R0, 56 (17%) resulted R1 parenchymal, 50 (15%) resulted R1 vascular, and 16 (5%) resulted both R1 parenchymal and R1 vascular. After a median follow-up of 33.5 months (range 6.1-107.6), the 5-year overall survival rates were 54%, 30%, 65%, and 36%, respectively for R0, R1 parenchymal, R1 vascular, and R1 parenchymal + R1 vascular (P = .031). Local recurrence rates were 3%, 14%, 4%, and 19%, respectively for R0, R1 parenchymal, R1 vascular, and R1 parenchymal + R1 vascular (P = .001) per patient, and 4%, 4%, 12%, and 18%, respectively for R0, R1 vascular, R1 parenchymal, and R1 parenchymal + R1 vascular (P = .001) per resection area. At multivariate analysis R1 parenchymal and R1 vascular + R1 parenchymal were independent detrimental factors. R1 vascular hepatectomy for hepatocellular carcinoma is not associated with increased local recurrence or decreased survival. Thus, detachment of hepatocellular carcinoma from intrahepatic vessels should be considered oncologically adequate.

Sections du résumé

BACKGROUND
R1 vascular resection for liver tumors was introduced in the early twenty-first century. However, its oncologic adequacy remains controversial. The aim of this study was to determine the oncologic adequacy of R1 vascular hepatectomy in hepatocellular carcinoma patients.
METHODS
A prospective cohort of patients with hepatocellular carcinoma resected between the years 2005 and 2015 was reviewed. R0 was any resection with a minimum 1 mm of negative margin. R1 vascular was any resection with tumor exposure attributable to the detachment from major intrahepatic vessel. R1 parenchymal was any resection with tumor exposure at parenchymal margin. The end points were the calculation of the local recurrence of R0, R1 parenchymal, and R1 vascular hepatectomy and their prognostic significances.
RESULTS
We analyzed 327 consecutive patients with 532 hepatocellular carcinoma and 448 resection areas. We found that 205 (63%) resulted R0, 56 (17%) resulted R1 parenchymal, 50 (15%) resulted R1 vascular, and 16 (5%) resulted both R1 parenchymal and R1 vascular. After a median follow-up of 33.5 months (range 6.1-107.6), the 5-year overall survival rates were 54%, 30%, 65%, and 36%, respectively for R0, R1 parenchymal, R1 vascular, and R1 parenchymal + R1 vascular (P = .031). Local recurrence rates were 3%, 14%, 4%, and 19%, respectively for R0, R1 parenchymal, R1 vascular, and R1 parenchymal + R1 vascular (P = .001) per patient, and 4%, 4%, 12%, and 18%, respectively for R0, R1 vascular, R1 parenchymal, and R1 parenchymal + R1 vascular (P = .001) per resection area. At multivariate analysis R1 parenchymal and R1 vascular + R1 parenchymal were independent detrimental factors.
CONCLUSION
R1 vascular hepatectomy for hepatocellular carcinoma is not associated with increased local recurrence or decreased survival. Thus, detachment of hepatocellular carcinoma from intrahepatic vessels should be considered oncologically adequate.

Identifiants

pubmed: 30691871
pii: S0039-6060(18)30798-0
doi: 10.1016/j.surg.2018.12.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

897-904

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Matteo Donadon (M)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy; Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Alfonso Terrone (A)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Fabio Procopio (F)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Matteo Cimino (M)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Angela Palmisano (A)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Luca Viganò (L)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy; Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Daniele Del Fabbro (D)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Luca Di Tommaso (L)

Humanitas University and Research Hospital, Rozzano, Milan, Italy; Department of Pathology, Humanitas University and Research Hospital, Rozzano, Milan, Italy.

Guido Torzilli (G)

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas University and Research Hospital, Rozzano, Milan, Italy; Humanitas University and Research Hospital, Rozzano, Milan, Italy. Electronic address: guido.torzilli@hunimed.eu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH